Key result
Enoxaparin saves ~$391 per DVT prevented vs. low-dose heparin after major trauma.
Why the study?
The cost-effectiveness of enoxaparin compared with low-dose heparin for thromboprophylaxis after major trauma, as well as the economic significance of major bleeding associated with LMWH, needed to be determined.
Does enoxaparin improve cost-effectiveness and prevent deep vein thromboses compared with low-dose heparin in critically ill trauma patients requiring thromboprophylaxis?
Does enoxaparin improve cost-effectiveness and prevent deep vein thromboses compared with low-dose heparin in critically ill trauma patients requiring thromboprophylaxis?
Answers are grounded in this paper and cite their sources.
A decision model analysis indicates that using enoxaparin over low-dose heparin for thromboprophylaxis after major trauma may result in net financial savings per DVT prevented despite higher drug costs and bleeding risks.
Objective To determine the cost-effectiveness of enoxaparin compared with low-dose-heparin (LDH) for thromboprophylaxis after major trauma and to assess the economic significance of major bleeding as a complication of the use of low-molecular-weight heparin (LMWH). Design Decision model analysis of the cost and efficacy of enoxaparin at preventing venous thromboembolism (VTE) and the risk and costs of major hemorrhage related to LMWH. The primary outcome was deep vein thromboses (DVTs) averted. Model estimates were based on data from prospective trials of LMWH and other studies of the financial ramifications of DVT and pulmonary embolism. Setting and patients Hypothetical cohort of 1,000 critically ill trauma patients requiring thromboprophylaxis. Interventions In the model, patients were managed with either LMWH or LDH. Measurements and main results The marginal cost-effectiveness of enoxaparin was calculated as the savings resulting from cases of DVT averted less the additional costs of both 1) LMWH and 2) major bleeding. This result is expressed as cost (or savings) per DVT prevented. Sensitivity analysis of the impact of the major clinical inputs on the cost-effectiveness was performed. The base case assumed that the incidence of DVT with LDH was 14.7%, that LMWH resulted in a relative risk reduction of DVT of 50%, but that enoxaparin nearly quadrupled the risk of bleeding. Despite the higher costs of enoxaparin, this tactic yielded a net savings of $391.23 per DVT prevented. For sensitivity analysis, model inputs were adjusted by 25% individually and then simultaneously. This demonstrated the model to be most sensitive to the calculated cost of a DVT. With the efficacy of LMWH reduced by 25% of the base-case estimate, enoxaparin resulted in a cost of $311.77 per DVT avoided. When all variables were skewed against LMWH, total outlays were trivial (approximately $85 per patient in the cohort). Neither the rate of increased bleeding with LMWH nor the costs incurred as a result of bleeding significantly altered the model's financial outcomes. Conclusions Reliance on enoxaparin represents a strategy for the prevention of VTE after trauma that may result in savings. Neither concerns about the higher cost of enoxaprin relative to LDH nor the financial implications of major bleeding should preclude the use of LWMH for thromboprophylaxis in trauma patients. Further studies are warranted to confirm the efficacy of enoxaparin.
No takes yet. Share an insight, caveat, or question.
Shorr et al. (2001) studied Major trauma requiring thromboprophylaxis (n=1,000). Enoxaparin (low-molecular-weight heparin) vs. Low-dose heparin (LDH) was evaluated on Cost (or savings) per deep vein thrombosis (DVT) prevented (Net savings of $391.23 per DVT prevented (assuming 50% RRR in DVT)). Enoxaparin for thromboprophylaxis after major trauma yielded a net savings of $391.23 per DVT prevented compared with low-dose heparin in a decision model.
Synapse has enriched 10 related papers. Consider them for comparative context: